Answers are grounded in this paper and cite their sources.
Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed, yet medication adherence varies. This study evaluated real-world adherence and persistence to semaglutide and empagliflozin among adults with T2D and assessed the associations between adherence and clinical outcomes. Patients and Methods: A retrospective observational study was performed using electronic health records and pharmacy dispensing data from a military hospital in Tabuk, Saudi Arabia, between July 1, 2023 and June 30, 2024. Adults with T2D (≥18 years old) prescribed semaglutide or empagliflozin were included. Medication adherence was quantified using proportion of days covered (PDC). Persistence was defined by absence of treatment gap ≥60 days. Associations between adherence and patient characteristics, and clinical out-comes, were examined. Results: Among 5087 patients (mean age 57.9 ± 12.3 years, mean T2D duration 10.3 ± 7.6 years), 4020 received empagliflozin and 1067 initiated semaglutide. Adherence (PDC ≥ 80%) was observed in 57.7% of semaglutide and 60% of empagliflozin users. Persistence was lower 40% (semaglutide) and 45% (empagliflozin) met the criteria. Sociodemographic variables were not significant predictors of medication adherence. Conclusion: Medication adherence and persistence to both semaglutide once-weekly injection and oral empagliflozin were suboptimal among T2D patients. Adherent patients to both medications experienced a significant improvement in glycemic control. Targeted strategies are needed to enhance patient motivation for consistent medication use and timely refills.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: